Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Chethana Kamath"'
Publikováno v:
Current Research in Pharmacology and Drug Discovery, Vol 3, Iss , Pp 100101- (2022)
Background: Patients with inflammatory bowel disease (IBD) often require the use of immunosuppressant medications that increase infection risk, leading to concerns over the safe use of IBD medications during the Coronavirus 19 (COVID-19) pandemic. Ob
Externí odkaz:
https://doaj.org/article/23d13205206c484ab3be8ee407f6f64c
Autor:
Chethana, Kamath, Amy, Liu
Publikováno v:
Pediatric Annals. 51
Musculoskeletal injuries are a common reason for emergency department and primary care visits in the pediatric population. The prevalence of these injuries is likely related to children and adolescents participating in sports activities, physical act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f261650c227d51ea092168d098f0d51b
https://doi.org/10.3928/19382359-20220711-01
https://doi.org/10.3928/19382359-20220711-01
Autor:
Saji Kurian, Forat Lutfi, Chethana Kamath, Marc Zumberg, Shuyao Zhang, Dae Jun Kim, Aisha Elfasi, Martina Murphy, Michael Setteducato, Vikas J Patel, Chintan Shah, Rohit Bishnoi
Publikováno v:
Cureus
Intravenous unfractionated heparin (UFH) remains one of the most commonly used anticoagulants in the hospital setting. The optimal protocol for initiation and maintenance of UFH has been difficult to determine. Over the past two decades, weight-based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67238e5011c839994644016e9cfe8171
https://doi.org/10.7759/cureus.8339
https://doi.org/10.7759/cureus.8339
Autor:
Forat Lutfi, Chethana Kamath, Aisha Alfasi, Michael Setteducato, Chintan Shah, Saji Kurian, Shuyao Zhang, Martina Murphy, Vikas J Patel, Rohit Boshnoi, Dae Jun Kim
Publikováno v:
Blood. 132:1251-1251
Introduction: At our institution, therapeutic use of unfractionated heparin (UFH) is administered by standard (target anti-Xa activity level 0.30 to 0.70 IU/mL) and low intensity (target anti-Xa activity level 0.25 to 0.35 IU/mL) protocols. In patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::014966245adb462cef05eaa429747a07
https://doi.org/10.1182/blood-2018-99-110232
https://doi.org/10.1182/blood-2018-99-110232